Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CDK14 | O94921 | 1/20 | 0.39 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28630813 | 0.77 | KMT2A (0.60) | TGM2LMNANPC1MEN1KMT2A | |
| SCHEMBL28619644 | 0.77 | KMT2A (0.60) | TGM2LMNANPC1MEN1KMT2A | |
| SCHEMBL28617369 | 0.77 | KMT2A (0.60) | TGM2LMNANPC1MEN1KMT2A | |
| SCHEMBL17327878 | 0.77 | TGM2 (0.63) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL20691193 | 0.76 | TGM2 (0.62) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL21179444 | 0.75 | GSTO1 (0.40) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL28620280 | 0.75 | TGM2 (0.61) | TGM2LMNANPC1RAB9AMEN1 | |
| SCHEMBL28619301 | 0.75 | TGM2 (0.61) | TGM2LMNANPC1RAB9AMEN1 | |
| SCHEMBL28624100 | 0.75 | B3GNT2 (0.47) | TGM2LMNANPC1RAB9AMEN1 | |
| SCHEMBL28627367 | 0.75 | TGM2 (0.47) | TGM2F13A1LMNATGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118754861-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩肿瘤学有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-111902403-B | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2023-04-25 | — | — | US | disclosed |
| EP-3740473-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | Aurigene Discovery Technologies Limited (IN) | 2020-11-25 | — | — | EP | disclosed |
| CN-111902403-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019142126-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | TGM2 2376/4885F13A1 4245/4885LMNA 1512/4885 |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | MCL1, ROS1, MKI67 | TGM2 2376/4885F13A1 4245/4885LMNA 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.